Filter your results
- 3
- 2
- 1
- 2
- 1
- 2
- 1
- 3
- 3
- 3
- 2
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancerBritish Journal of Clinical Pharmacology, 2016, 81 (5), pp.941-948. ⟨10.1111/bcp.12875⟩
Journal articles
hal-01252102v1
|
||
|
Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancerOncology Letters, 2016, 12 (3), pp.2028-2032. ⟨10.3892/ol.2016.4891⟩
Journal articles
hal-01418865v1
|
||
Trastuzumab (T) and everolimus (E) pharmacokinetics (PK) in HER2 positive (+) primary breast cancer (BC) patients (pts): Unicancer RADHER trial results2013 ASCO Annual Meeting, May 2013, Chicago, Il, United States. pp.CDROM
Conference papers
hal-00831929v1
|